Virtual Conference
Pharma Conference 2022

Syeda Shahmoona Tirmizi

Hamdard University Hospital, Pakistan

Title: Efficacy of secukinumab in moderate-to-severe psoriasis


Background: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy and a favourable safety profile in the treatment of moderate-to-severe psoriasis.

Objective: To assess the efficacy of secukinumab in moderate-to-severe psoriasis.

Methods: In the interventional study, Psoriasis Area and Severity Index (PASI) 75 responders at Week 12 continued receiving subcutaneous secukinumab until Year 1. Here, we focus on the 300 mg fixed-interval (every 4 weeks) treatment, the recommended per label dose. Efficacy data are primarily reported as observed.

Results: Total 138 patients entered the study and at the end of 12 months, 126 patients completed 300 mg (every 4 weeks) treatment. PASI 75/90/100 responses at Year 1 (88.9%, 68.5% and 43.8%, respectively) were sustained (88.5%, 66.4% and 41%).The average improvement in mean PASI was approximately 90% through 1 year. DLQI (dermatology life quality index) 0/1 response also sustained through 1 year (72.7% at Year 1). The safety profile of secukinumab remained favourable, with no cumulative or unexpected safety concerns identified.

Conclusion: Secukinumab 300 mg treatment delivered high and sustained levels of skin clearance and improved quality of life over 1 year in patients with moderate-to-severe psoriasis.


To be added